Follow

Arctic Bioscience AS - Notice of extraordinary general meeting – new date

25 October 2021 - 12:20

Notice of extraordinary general meeting (EGM) - new date reference is made to the stock exchange announcement from Arctic Bioscience AS (the Company), published 19 October at 14:18 CET "Notice of extraordinary general meeting: Marita Holstad proposed as new board member ".

Due to complications in distribution, the notice and regulatory documentation did not reach all shareholders of Arctic Bioscience AS.

Thus, in order to ensure that the EGM is convened in accordance with prevailing regulations, the Board of Directors have decided that the EGM is moved to 10 November 2021 and a new Notice is attached to this release.

Due to the corona pandemic, the Board of Directors has resolved that the Extraordinary General Meeting will be held as a digital meeting in accordance with section 5-8 of the Norwegian Private Limited Liability Company's Act (as amended as from 1 June 2021).

Shareholders are encouraged to cast their votes in advance of the General Meeting or grant the Chair of the Board a proxy, with or without voting instructions.

Deadline for registration of attendance, advance votes, proxy or instructions is 9 November 2021 at 3pm (CET). For attendance to the live event, please follow the instruction in the notice.

The EGM will be on 10 November at 1pm CET on Microsoft Teams. Please follow the instructions in the Notice for attendance.

For further information, please contact:

Danielle Glenn

CFO of Arctic Bioscience AS

Mobile: +47 909 98 201

Email: [email protected]

About Arctic Bioscience

Arctic Bioscience is a biotech company developing pharmaceutical and nutraceutical products based on the unique properties of herring roe oil, composed of complex bioactive marine compounds, including lipids essential to maintaining cell membranes. The nutraceutical products contain lipids which contribute to the normal functioning of brain, heart and vision.

The company is developing a novel drug candidate (HRO350) for mild-to-moderate psoriasis, a large global patient population where there is substantial need for effective, convenient and cost-effective new medicines with beneficial safety profiles. Nutraceuticals from Arctic Bioscience are sold worldwide as bulk ingredients to other companies making dietary supplements (B2B) and as finished goods under the ROMEGA brand (B2C), with significant expansion potential all channels and regions.

To support its long-term growth strategy, Arctic Bioscience is planning a state-of-the-art manufacturing facility in Ørsta. Easy access to the raw material and proprietary production processes will increase control of the value chain, improve margins and enable large-scale, high-quality manufacturing.

Arctic Bioscience is led by a highly competent team with significant expertise developing marine oils and extensive experience from some of the world's leading pharmaceutical, technology and financial services companies.

This information is subject of the disclosure requirements pursuant to section 5 -12 of the Norwegian Securities Trading Act.

Provided by: Cision
Euronext Growth Oslo (Norway)
Arctic Bioscience AS
Arctic Bioscience produces unique pharmaceutical and nutraceutical products based on bioactive marine compounds. The Company is developing a novel, cost-efficient oral treatment for mild-to-moderate psoriasis – a large global market with significant unmet medical need....
Learn more about company

Related news

We use cookies to make your experience using IPOhub better. By using our site you agree to our use of cookies. Learn More